Could Zoetis Inc. (ZTS) Change Direction After Achieving All-Time High?

February 15, 2018 - By Dolores Ford

Investors sentiment increased to 1.1 in 2017 Q3. Its up 0.06, from 1.04 in 2017Q2. It increased, as 41 investors sold Zoetis Inc. shares while 233 reduced holdings. 62 funds opened positions while 240 raised stakes. 440.74 million shares or 0.80% less from 444.27 million shares in 2017Q2 were reported.
Registered Inv Advisor Inc owns 8,811 shares. Howe Rusling Inc has 0% invested in Zoetis Inc. (NYSE:ZTS). Virtu Limited Co, New York-based fund reported 11,692 shares. Advsr Asset holds 15,314 shares. Amer Intl Grp Inc accumulated 0.05% or 214,998 shares. Panagora Asset Mngmt Inc accumulated 779,180 shares or 0.2% of the stock. Btc stated it has 48,537 shares. Barrett Asset Mgmt Ltd reported 13,400 shares or 0.06% of all its holdings. State Street reported 0.11% stake. Swiss Savings Bank invested in 0.13% or 1.81M shares. Davenport & Ltd Liability holds 418,820 shares. 118,593 were reported by Windward Cap Co Ca. Voya Invest Mgmt Ltd Liability Corporation accumulated 5.22M shares or 0.72% of the stock. Boston Advsrs Ltd Liability Corp holds 0.12% or 82,051 shares. Taurus Asset Mngmt Ltd Liability Corporation holds 5,927 shares or 0.06% of its portfolio.

The stock of Zoetis Inc. (NYSE:ZTS) reached all time high today, Feb, 15 and still has $84.13 target or 9.00 % above today’s $77.18 share price. This indicates more upside for the $37.61B company. This technical setup was reported by Barchart.com. If the $84.13 PT is reached, the company will be worth $3.38B more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 3.65% or $2.72 during the last trading session, reaching $77.18. About 2.51 million shares traded or 4.26% up from the average. Zoetis Inc. (NYSE:ZTS) has risen 29.89% since February 15, 2017 and is uptrending. It has outperformed by 13.19% the S&P500.

Zoetis Inc. (NYSE:ZTS) Ratings Coverage

Among 21 analysts covering Zoetis Inc (NYSE:ZTS), 16 have Buy rating, 0 Sell and 5 Hold. Therefore 76% are positive. Zoetis Inc had 70 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Tuesday, January 16. Cantor Fitzgerald maintained Zoetis Inc. (NYSE:ZTS) on Wednesday, September 6 with “Buy” rating. The rating was maintained by Piper Jaffray with “Buy” on Friday, July 14. Zacks downgraded the shares of ZTS in report on Monday, September 7 to “Hold” rating. On Wednesday, August 9 the stock rating was maintained by Craig Hallum with “Buy”. The stock of Zoetis Inc. (NYSE:ZTS) has “Buy” rating given on Tuesday, January 2 by Craig Hallum. The rating was maintained by Piper Jaffray on Monday, July 24 with “Buy”. As per Thursday, August 24, the company rating was maintained by Cowen & Co. The stock of Zoetis Inc. (NYSE:ZTS) has “Neutral” rating given on Thursday, August 4 by Citigroup. The firm earned “Buy” rating on Monday, July 10 by Cowen & Co.

More recent Zoetis Inc. (NYSE:ZTS) news were published by: Nasdaq.com which released: “Zoetis (ZTS) Warming Up to Q4 Earnings: What’s in Store?” on February 09, 2018. Also Zacks.com published the news titled: “Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View” on February 15, 2018. Streetinsider.com‘s news article titled: “Zoetis Inc. (ZTS) PT Raised to $90 at Cantor Fitzgerald on 4Q Beat; ‘Positive …” with publication date: February 15, 2018 was also an interesting one.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. The company has market cap of $37.61 billion. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. It has a 40.64 P/E ratio. The firm also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.